枳朴六君子汤加味联合TACE治疗原发性肝癌临床研究

Clinical Study on Modified Zhipu Liujunzi Tang Combined with TACE for Primary Liver Cancer

目的:观察枳朴六君子汤加味联合肝动脉化疗栓塞(TACE)术治疗原发性肝癌的临床疗效。方法:选取行TACE术的原发性肝癌患者68例,按随机数字表法分为观察组和对照组各34例。对照组给予TACE术治疗,观察组在对照组基础上给予枳朴六君子汤加味治疗。比较2组临床疗效及治疗前后血清细胞间黏附分子-1(ICAM-1)、血管内皮生长因子(VEGF)、转化生长因子-β1(TGF-β1)含量,统计中医证候积分。结果:观察组总有效率为85.30%,对照组为61.77%,2组比较,差异有统计学意义(P<0.05)。治疗前,2组血清ICAM-1、VEGF、TGF-β1水平比较,差异无统计学意义(P>0.05)。治疗后,2组血清ICAM-1、VEGF、TGF-β1水平低于治疗前(P<0.05),观察组血清ICAM-1、VEGF、TGF-β1水平低于对照组(P<0.05)。治疗前,2组中医证候积分比较,差异无统计学意义(P>0.05)。术后2周、4周,2组中医证候积分逐渐降低,且观察组术后4周中医证候积分低于对照组,差异均有统计学意义(P<0.05)。结论:枳朴六君子汤加味可以降低原发性肝癌TACE术后血清中ICAM-1、VEGF、TGF-β1含量水平,提高临床疗效。

Objective:To observe the clinical effect of modified Zhipu Liujunzi tang combined with transcatheter hepatic arterial chemoembolization(TACE)for primary liver cancer.Methods:A total of 68 cases of patients with primary liver cancer undergoing TACE were selected and divided into the observation group and the control group according to the random number table method,34 cases in each group.The control group was treated with TACE,and the observation group was additionally treated with modified Zhipu Liujunzi tang based on the treatment of the control group.The changes in the content levels of intercellularadhesionmolecule-1(ICAM-1),vascularendothelialgrowthfactor(VEGF)andtransforminggrowthfactor-β1(TGF-β1)in serum before and after treatment as well as the clinical effect in the two groups were compared;Chinese medicine syndrome scores were counted.Results:The total effective rate was 85.30%in the observation group and 61.77%in the control group,the difference being significant(P<0.05).Before treatment,there was no significant difference being found in the comparison of the levels of ICAM-1,VEGF and TGF-β1 in serum between the two groups(P>0.05).After treatment,the levels of ICAM-1,VEGF and TGF-β1 in serum in the two groups were lower than those before treatment(P<0.05),and the levels in the observation group were lower than those in the control group(P<0.05).Before treatment,there was no significant difference being found in the comparison of Chinese medicine syndrome scores between the two groups(P>0.05).Two and four weeks after surgery,Chinese medicine syndrome scores in the two groups were decreased gradually,and the score at four weeks after surgery in the observation group was lower than that in the control group,differences being significant(P<0.05).Conclusion:Modified Zhipu Liujunzi tang can reduce the content levels of ICAM-1,VEGF and TGF-β1 in serum of patients with primary liver cancer after TACE and improve the clinical effect.